Your search for Warfarin returned 109 results

End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.

The Food and Drug Administration (FDA) has approved updated labeling for several hepatitis C virus (HCV) infection treatments.

The Food and Drug Administration (FDA) is recommending that patients avoid the concomitant use of sodium polystyrene sulfonate with other oral medications.

The primary safety endpoint was defined as time to major bleeding events and clinically relevant non-major bleeding events when compared to triple therapy with warfarin.

The main outcomes and measures were intraocular bleeding events and associated risk ratio for NOACs, compared with warfarin.

The researchers assessed the relative risk for influenza and ILI on the basis of body mass index and determined seroconversion and seroprotection rates using pre-vaccination and 26-35 day post-vaccination serum samples.

Patients taking apixaban showed significantly less intracranial hemorrhage (0.33% per year) vs. patients taking warfarin (0.80% per year) no matter the type and location.

Study patients were randomized to Pradaxa 150mg twice daily or warfarin (target INR 2-3) and remained on this treatment for the trial duration.

The researchers searched the U.S. Medicare database for NVAF patients 65 years of age and older who were newly prescribed one of the following medications: apixaban, dabigatran, rivaroxaban, or warfarin.

Jan Steffel, from the TIMI Study Group, Boston, MA, and colleagues presented on the safety of edoxaban in the context of atrial fibrillation (AF) ablation.